The Oncodetect test is available for order across multiple solid tumors
Exact Sciences Corp , a leading provider of cancer screening and diagnostic tests, announced the launch of Oncodetect —a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing.
Health Technology Insights: bioAffinity Boosts CyPath Lung Test Speed and Cuts Costs
The Oncodetect test delivers clear “Detected” or “Not Detected” results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. Notably, patients who test positive for ctDNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results1. Highly sensitive and personalized, the test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA—down to 1 ctDNA molecule in 20,000 cfDNA‡ molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone1,2.
“Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions,” said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. “After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.”
Health Technology Insights: Instem Expands Preclinical Platform for Regulatory Needs
Backed by robust clinical validation, including data from the Alpha-CORRECT study—one of the longest-followed MRD cohorts for CRC recurrence with nearly five years of follow-up—the Oncodetect test enhances understanding of cancer recurrence and helps support timely, personalized treatment decisions. Exact Sciences is actively working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation.
“Exact Sciences is a longtime trusted partner in addressing the critical unmet needs in colorectal cancer care, ensuring patients have the insights they need to navigate treatment with confidence,” said Vanessa Ghigliotty, Certified Patient Navigator & Chair, Patient Advisory Board, GI Cancers Allianc. “For those facing the uncertainty of recurrence, tumor-informed MRD tests like the Oncodetect test can provide clear, timely answers—empowering patients to take an active role in their care and receive the right treatment at the right time for better outcomes.”
The Oncodetect test builds on 20 years of genomic testing excellence established by the Oncotype DX Breast Recurrence Score® test. Integrated into a world-class digital experience, supported by the ExactNexus™ technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra® (comprehensive genomic profiling) and Riskguard® (hereditary cancer testing). With more than 3 million American patients3 eligible for MRD testing, Exact Sciences is well-positioned to shape the future of personalized care.
Health Technology Insights: Provista and Coral Partner to Optimize Pharmacy and Infusion Costs
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
